MedTrace Logo

Positron Emission Tomography in Monitoring Treatment Response in Women With Newly Diagnosed Breast Cancer

NCT01018251 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2015-12-15

No results posted yet for this study

Summary

This study will investigate the sensitivity and specificity of FLT-PET/CT in primary breast cancer detection and in the use of FLT-PET in monitoring how well a breast tumor respond to treatment. We will compare this technique with other imaging modalities as well as with tissue collection (during a biopsy). We will recruit women with a newly diagnosed invasive breast cancer, who are able to tolerate undergoing a PET/CT (possibly two scans) scan,

Conditions

  • Adult Women With a New Diagnosis of Invasive Breast Cancer (Have Not Undergone Treatment)

Interventions

OTHER

3'-deoxy-3'-[18F]fluorothymidine

Given IV

PROCEDURE

Positron Emission Tomography/computed tomography

RADIATION

FLT-PET/CT

Sponsors & Collaborators

  • Abramson Cancer Center at Penn Medicine

    lead OTHER

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-03-31
Primary Completion
2011-06-30
Completion
2011-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01018251 on ClinicalTrials.gov